Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].

M P Goetz, M Toi, J Huober, J Sohn, O Trédan, I H Park, M Campone, S-C Chen, L M Manso, S Paluch-Shimon, O C Freedman, J O'Shaughnessy, X Pivot, S M Tolaney, S A Hurvitz